2018 Annual General Meeting
Zur Rose shareholders adopt all proposals
At the 25th Annual General Meeting of Shareholders of Zur Rose Group AG, the shareholders approved the Management Report and the company and consolidated financial statements for 2017. With regard to the appropriation of retained earnings, the proposal to carry forward the entire amount available to the General Meeting of Shareholders was adopted. In addition, the shareholders ratified the actions of the Board of Directors and Group Management in the reporting year.
The General Meeting of Shareholders also had to decide on the maximum fixed compensation for the members of the Board of Directors and Group Management for the current 2018 financial year, for the coming 2019 financial year and on the total amount of variable compensation for the members of Group Management for the 2017 financial year. The General Meeting of Shareholders adopted the proposals of the Board of Directors and approved the five agenda items. The Compensation Report for the 2017 financial year was also endorsed in a consultative vote.
The Board members standing for another term of one year, Prof. Volker Amelung, Dr. Heinz O. Baumgartner, Prof. Stefan Feuerstein, Vanessa Frey, Walter Oberhänsli and Dr. Thomas Schneider, were re-elected. The mandate of the incumbent Chairman of the Board of Directors, Prof. Stefan Feuerstein, was also renewed for another term of one year. Dr. Lukas Wagner opted not to stand for re-election as a Board member due to age. The Board of Directors thanked him for his long-standing commitment to Zur Rose. As members of the Compensation Committee, Prof. Stefan Feuerstein, Vanessa Frey and Dr. Thomas Schneider were re-elected for another term of office of one year.
The shareholders confirmed Ernst & Young AG, Zurich, as auditors for another term of one year. In addition, Fürer Partner Advocaten, Frauenfeld, were re-elected as independent proxy for another term of one year.
Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail: firstname.lastname@example.org, telephone: +41 52 724 00 64
Lisa Lüthi, Head of Corporate Communications
e-mail: email@example.com, telephone: +41 52 724 08 14
15 August 2018 Half-year report (analyst and media conference)
24 October 2018 Q3 Trading Update
Zur Rose Group
Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose Group is Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.
The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. Customers in Germany and Austria are primarily supplied from Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 1000 people at its various locations, Zur Rose Group generated revenue of CHF 983 million in 2017. Zur Rose Group AG's shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange. More information at zurrosegroup.com.